WO2006094451A1 - Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension - Google Patents
Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension Download PDFInfo
- Publication number
- WO2006094451A1 WO2006094451A1 PCT/CN2006/000329 CN2006000329W WO2006094451A1 WO 2006094451 A1 WO2006094451 A1 WO 2006094451A1 CN 2006000329 W CN2006000329 W CN 2006000329W WO 2006094451 A1 WO2006094451 A1 WO 2006094451A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrochloric acid
- aqueous solution
- hypertension
- medicament
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Definitions
- the present invention relates to the use of hydrochloric acid in the preparation of a medicament for the treatment of diseases such as hypertension and stones.
- the object of the present invention is to provide an application of hydrochloric acid in the preparation of a medicament for treating hypertension.
- the formation of hypertension is based on the following mechanisms: 1. Binder calcium carbonate and calcium oxalate formed by decomposition of calcium bicarbonate in water and food to metabolize human body (such as cholesterol) Crystallization, etc., and the solid matter entering the human body adhere to the inner wall of the arterial blood vessel and the capillary. As the age increases, the scale on the inner wall of the arterial blood vessel and the capillary becomes thicker and thicker, and the pore diameter of the blood vessel becomes smaller and smaller, thereby making Poor blood flow, increased blood pressure;
- these calcium carbonate and calcium oxalate are deposited in organs such as kidney, liver and gallbladder, and kidney stones, liver stones and gallstones are formed.
- hydrochloric acid is the most ideal substance for dissolving ⁇ ⁇ and calcium oxalate in human body.
- hydrochloric acid is adsorbed on the inner wall by a protective membrane of blood vessels, which can repair damaged blood vessels and restore the blood vessels to their own elasticity.
- hydrochloric acid helps dissolve kidney stones, liver stones and gallstones, thereby relieving or eliminating stones. Therefore, in a first aspect of the invention, there is provided a use of hydrochloric acid for the preparation of a medicament for the treatment of hypertension.
- the pH of the aqueous solution is controlled to be 3-6.9 (more preferably 4-6. 5).
- the pH of the aqueous solution is controlled at 6. 5 ⁇ 6.
- the drug is in an oral liquid dosage form.
- the medicament is an injectable dosage form.
- the drug is an aqueous solution of hydrochloric acid having a pH of from 3 to 9.9 (more preferably, pH 4 to 6. 5), and the aqueous solution conforms to drinking water standards.
- the drug is an aqueous solution of hydrochloric acid having a pH of 3.9, and the aqueous solution further contains an additional therapeutic agent for hypertension which is stable in the pH range.
- the pH of the aqueous solution is 4 - 6 ⁇ 5 or 6. 5 - 6.
- a preparation for treating hypertension said preparation being an aqueous solution of hydrochloric acid of pH 3 - 6.9, and said aqueous solution further comprising an additional high which is stable in said pH range Blood pressure therapeutic agent.
- the additional therapeutic agent for hypertension is selected from, but not limited to, amlodipine, Benazepril, Captopril, clonidine (Clonidine), Enalaprilat, Felodipine, Guanazodine, Indanidine, Indapamide, Minoxidil ), Nitrendipine, Perindopril, Proroxan, Reserpiline, Triraoxamine, Triparaide, Util Utibapril, Zabiciprilat or a combination thereof PT/CN2006/000329 More preferably, the formulation is an injection.
- the use of hydrochloric acid in the manufacture of a medicament for the treatment of a stone disease is selected from the group consisting of: kidney stones, liver stones, or gallstones.
- the singularity of the aqueous solution of the aqueous solution is controlled to be 3-6. 9 (more preferably 4-6. 5). .
- the aqueous solution containing hydrochloric acid can be used as edible hydrochloric acid as long as the pH of the aqueous solution is controlled at 6. 5 ⁇ 6. Drink water directly.
- the drugs can be used in the preparation of oral solutions or injections as well as other dosage forms.
- a therapeutic salt acid aqueous solution it is best to drink no less than 1500ml per day for consumption of hypertension or stones, and it is divided into 3 to 6 times for drinking, and 3 to 6 months for a course of treatment.
- the recommended daily dose is 500ml, divided into two injections, intravenous drip, for 2 to 3 months for a course of treatment.
- high blood pressure can be reduced by 1/4 after 1 year, and halved after 2 years. After three years, generally only take maintenance dose or exempt from antihypertensive drugs, and blood pressure returns to normal.
- the above-mentioned aqueous solution containing hydrochloric acid can be continuously, stably and in large quantities by using a P H value control device.
- the injection can be prepared by a pharmaceutically acceptable method from hydrochloric acid, as long as it is controlled to have a pH of from 3 to 6.9 (more preferably from 4 to 6. 5).
- hydrochloric acid water from tap water, it is generally necessary to provide a purification device at the front end to meet the hygienic standard of national drinking water.
- the hydrochloric acid of the present invention can also be applied to other solutions, such as physiological saline, dextrose solution, beverage, etc., and the method for preparing hydrochloric acid water is the same as above, as long as the pH of the oral solution or the injection is controlled. .
- the edible hydrochloric acid water according to the present invention generally does not allow heating to be consumed, because heating causes the hydrochloric acid to volatilize and loses its therapeutic effect. Also do not drink beverages and tea that are prone to scaling, and theophylline and hydrochloric acid will neutralize and lose their effect.
- the present invention treats 126 cases of edible salt Hypertensive patients with acid water were clinically observed, including 87 males and 39 females, with an average age of 68.2 years and an age range of 51 to 81 years.
- the present invention has clinically observed a plurality of patients with kidney stones, liver stones and/or gallstones drinking drinking hydrochloric acid, and the results also show that drinking aqueous hydrochloric acid helps to alleviate or eliminate stones.
- the medicine prepared by the hydrochloric acid preparation of the invention is safe and reliable for treating hypertension and calculus, has exact and obvious effects, and has obvious improvement effect on hypertension patients suffering from arteriosclerosis, and can convert calcium salts harmful to the human body into The body needs calcium.
- the high-purity hydrochloric acid was added to a hydrochloric acid solution diluted to 2% in drinking water, and filled in a hydrochloric acid solution with a flow controller.
- the above hydrochloric acid solution and drinking water are mixed at a certain flow ratio through a pipe, and a pH detector is disposed at the end of the pipe.
- the hydrochloric acid aqueous solution was controlled to have a pH of 6. 5 to 6. 9.
- Table 1 shows the improvement of hypertension in some cases after drinking the edible hydrochloric acid water of the present invention.
- Table 1 Edible hydrochloric acid for the treatment of hypertension
- Example 3 The high-purity hydrochloric acid was added to a hydrochloric acid solution diluted to 2% in drinking water, and filled in a hydrochloric acid solution with a flow controller. The hydrochloric acid solution and the drinking water are mixed at a certain flow ratio through a pipe, and a pH detector is disposed at the end of the pipe. The hydrochloric acid aqueous solution was controlled to have a pH of 4.0 to 6.5 to prepare edible hydrochloric acid water.
- the patients with multiple stones were treated with the edible hydrochloric acid prepared above.
- the patient can drink 2000ml daily, drink 500ml each morning and one hour before the Chinese food, and drink lOOOralo one hour before dinner.
- the pH of the drinking hydrochloric acid solution is lower than 6.5, the drinking amount can be appropriately reduced.
- the patient should drink 1000 ml per day, drink 250 ml each morning, one hour before the Chinese food, and 500 ml one hour before the evening meal.
- Liu ⁇ 1.8 65 Drinking for one year is ⁇ 1.1, drinking for two years is 0.6 Liu ⁇ 1.1 62 drinking 1.5 years all disappear
- a 500 ml aqueous solution of pH 6.9 in hydrochloric acid was added to a tablet of the commercially available hypertension drug indapamide (2.5 mg) to form a combination preparation containing hydrochloric acid and indapamide.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200701936A EA012616B1 (ru) | 2005-03-10 | 2006-03-06 | Применение соляной кислоты для изготовления лекарственного средства для лечения повышенного давления |
MX2007010918A MX2007010918A (es) | 2005-03-10 | 2006-03-06 | El uso del acido clorhidrico para la elaboracion de un medicamento para el tratamiento de la hipertension. |
AU2006222417A AU2006222417A1 (en) | 2005-03-10 | 2006-03-06 | The use of hydrochloric acid for the manufacture of a medicament for the treatment of hypertension |
US11/908,053 US20080317871A1 (en) | 2005-03-10 | 2006-03-06 | Use of Hydrochloric Acid For the Manufacture of a Medicament For the Treatment of Hypertension |
JP2008500030A JP2008532952A (ja) | 2005-03-10 | 2006-03-06 | 高血圧治療のための薬剤の製造における塩酸の適用 |
EP06705725A EP1864671A4 (en) | 2005-03-10 | 2006-03-06 | USE OF HYDROCHLORIC ACID FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HYPERTENSION |
BRPI0608022-7A BRPI0608022A2 (pt) | 2005-03-10 | 2006-03-06 | processo para fabricação de um medicamento para tratar hipertensão, formulação anti-hipertensão e processo para fabricação de um medicamento para tratar cálculo |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510049329.8 | 2005-03-10 | ||
CNA2005100493298A CN1830454A (zh) | 2005-03-10 | 2005-03-10 | 盐酸在制备治疗高血压药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006094451A1 true WO2006094451A1 (fr) | 2006-09-14 |
Family
ID=36952948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2006/000329 WO2006094451A1 (fr) | 2005-03-10 | 2006-03-06 | Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080317871A1 (zh) |
EP (1) | EP1864671A4 (zh) |
JP (1) | JP2008532952A (zh) |
KR (1) | KR20070116087A (zh) |
CN (1) | CN1830454A (zh) |
AU (1) | AU2006222417A1 (zh) |
BR (1) | BRPI0608022A2 (zh) |
EA (1) | EA012616B1 (zh) |
MX (1) | MX2007010918A (zh) |
WO (1) | WO2006094451A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101234123A (zh) * | 2008-02-02 | 2008-08-06 | 王德寿 | 一定浓度的盐酸水在治疗血管疾病中的应用 |
WO2010009589A1 (zh) * | 2008-07-21 | 2010-01-28 | Liu Zhiren | 盐酸在制备治疗胃炎、肠炎和脉管炎药物中的应用 |
CN105902565A (zh) * | 2016-05-11 | 2016-08-31 | 吴健忠 | 一种逆转动脉及其他软组织硬化的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301545A (zh) * | 1999-12-27 | 2001-07-04 | 王德山 | 一种复方降血压药 |
US20030178030A1 (en) * | 2002-03-20 | 2003-09-25 | Constantz Brent R. | Methods and devices for the in situ dissolution of renal calculi |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300361B1 (en) * | 1990-07-25 | 2001-10-09 | Novartis Ag | Stabilized pharmaceutical compositions comprising acid donors |
US20040115134A1 (en) * | 1999-06-22 | 2004-06-17 | Elan Pharma International Ltd. | Novel nifedipine compositions |
JP2002255801A (ja) * | 2000-12-26 | 2002-09-11 | Mitsukan Group Honsha:Kk | 高血圧予防用組成物 |
US7141251B2 (en) * | 2001-04-06 | 2006-11-28 | Cytorex Biosciences, Inc. | Pharmacologically active strong acid solutions |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
-
2005
- 2005-03-10 CN CNA2005100493298A patent/CN1830454A/zh active Pending
-
2006
- 2006-03-06 AU AU2006222417A patent/AU2006222417A1/en not_active Abandoned
- 2006-03-06 BR BRPI0608022-7A patent/BRPI0608022A2/pt not_active Application Discontinuation
- 2006-03-06 JP JP2008500030A patent/JP2008532952A/ja active Pending
- 2006-03-06 MX MX2007010918A patent/MX2007010918A/es not_active Application Discontinuation
- 2006-03-06 WO PCT/CN2006/000329 patent/WO2006094451A1/zh active Application Filing
- 2006-03-06 EA EA200701936A patent/EA012616B1/ru not_active IP Right Cessation
- 2006-03-06 US US11/908,053 patent/US20080317871A1/en not_active Abandoned
- 2006-03-06 EP EP06705725A patent/EP1864671A4/en not_active Withdrawn
- 2006-03-06 KR KR1020077023137A patent/KR20070116087A/ko not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1301545A (zh) * | 1999-12-27 | 2001-07-04 | 王德山 | 一种复方降血压药 |
US20030178030A1 (en) * | 2002-03-20 | 2003-09-25 | Constantz Brent R. | Methods and devices for the in situ dissolution of renal calculi |
Non-Patent Citations (2)
Title |
---|
FAN Y.: "The determination of free chlorine in food additive hydrochloride acid", CHINA CHLOR-ALKALI, no. 2, February 2003 (2003-02-01), pages 34 - 36, XP008120850 * |
See also references of EP1864671A4 * |
Also Published As
Publication number | Publication date |
---|---|
KR20070116087A (ko) | 2007-12-06 |
EP1864671A1 (en) | 2007-12-12 |
EA200701936A1 (ru) | 2008-02-28 |
BRPI0608022A2 (pt) | 2009-11-03 |
JP2008532952A (ja) | 2008-08-21 |
EA012616B1 (ru) | 2009-10-30 |
AU2006222417A1 (en) | 2006-09-14 |
CN1830454A (zh) | 2006-09-13 |
MX2007010918A (es) | 2008-03-13 |
US20080317871A1 (en) | 2008-12-25 |
EP1864671A4 (en) | 2010-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2454996C2 (ru) | Применение ксантогумола и изоксантогумола в качестве активного вещества для профилактики и/или борьбы с заболеваниями печени | |
CN105263579B (zh) | 左西替利嗪和孟鲁司特在治疗血管炎中的用途 | |
RU2668882C2 (ru) | Жидкая фармацевтическая композиция | |
JP2013541583A (ja) | 組み合わせ組成物 | |
WO2006094451A1 (fr) | Utilisation d’acide chlorhydrique pour la fabrication d’un medicament pour le traitement de l'hypertension | |
JP2024026871A (ja) | 慢性便秘症を治療するための医薬組成物 | |
Offerhaus | Drugs for the elderly | |
US11864570B2 (en) | Therapeutic composition including carbonated solution | |
WO2009094811A1 (fr) | Préparation d'un mélange acide de gelée royale et son application | |
HO et al. | Massive Amikacin" Overdose" | |
WO2009100591A1 (zh) | 一定浓度的盐酸水在治疗血管疾病中的应用 | |
GB2435418A (en) | Composition for preventing and alleviating alcohol hangover | |
JP6184960B2 (ja) | メラトニンの新規用途 | |
US20220160619A1 (en) | Effervescent Drug Formulations | |
WO2008043243A1 (fr) | Utilisation d'acide chlorhydrique dans la fabrication de médicament destiné au traitement de maladie entraînée par... | |
RU2177320C1 (ru) | Средство, ослабляющее выраженность постинтоксикационного алкогольного синдрома | |
JP2004538239A (ja) | 肝線維症および肝硬変の処置および予防のための薬剤組成物 | |
CN115768414A (zh) | 氨苯砜制剂及其使用方法 | |
JP2007520560A (ja) | 疼痛性障害の処置のための方法および組成物 | |
Canty et al. | Postoperative pain therapy | |
JP2010159216A (ja) | 鎮痛剤及び鎮痛システム | |
CN106552225A (zh) | 一种快速化解结石的药物配方 | |
US7718191B2 (en) | Pharmaceutical product which is used to reduced or stop moderate or severe snoring | |
Sloan et al. | Selected Therapeutic Problems | |
CN102366620A (zh) | 治疗癫痫病的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008500030 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/010918 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11908053 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006222417 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006705725 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1200702070 Country of ref document: VN Ref document number: 1020077023137 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200701936 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2006222417 Country of ref document: AU Date of ref document: 20060306 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006222417 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2006705725 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0608022 Country of ref document: BR Kind code of ref document: A2 |